Want to see BAX full AI Analyst Report?
Sales by Segment
Shows how sales are distributed across various business areas, indicating which segments are performing well and contributing most to overall revenue.The headline is divergence: Pharmaceuticals is the clearest growth engine (helped by drug‑compounding momentum), while Medical Products & Therapies is lagging due to infusion-system disruption and the Novum shipment/installation hold. HST is volatile and timing‑driven—recoveries in some quarters are offset by delayed government and large‑deal orders. The big jump in “Other” looks like timing/one‑offs (TSA/reimbursement and similar items) that mask roughly flat organic sales; management expects a stronger second half but Novum returns and supply risks keep upside uncertain.
Date | Medical Products and Therapies | Healthcare Systems and Technologies | Pharmaceuticals | Other |
|---|---|---|---|---|
Jun 30, 2026 | $2.08B | $801.00M | $0.00 | $83.00M |
Mar 31, 2026 | $1.28B | $705.00M | $621.00M | $90.00M |
Dec 31, 2025 | $1.39B | $827.00M | $668.00M | $91.00M |
Sep 30, 2025 | $1.33B | $773.00M | $632.00M | $101.00M |
Jun 30, 2025 | $1.32B | $767.00M | $612.00M | $111.00M |
Mar 31, 2025 | $1.26B | $704.00M | $581.00M | $78.00M |
Dec 31, 2024 | $1.31B | $784.00M | $643.00M | $12.00M |
Sep 30, 2024 | $1.34B | $752.00M | $588.00M | $17.00M |
Jun 30, 2024 | $1.32B | $748.00M | $602.00M | $22.00M |
Mar 31, 2024 | $1.23B | $667.00M | $578.00M | $16.00M |